CFO transition
Ovid Therapeutics Inc. CFO transition: Charles Carter to succeed Jeffrey Rona
Ovid Therapeutics Inc. reported in a Form 8-K filed July 8, 2026 that Charles Carter will succeed Jeffrey Rona as Chief Financial Officer, principal financial officer, principal accounting officer and secretary, effective July 6, 2026.
In the filing's words
the Company’s Board of Directors (the “Board”) appointed Charles Carter, the Company’s Senior Vice President of Finance and Financial Planning, as the Company’s Chief Financial Officer, principal financial officer, principal accounting officer and secretary, effective as of the Separation Date.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Ovid Therapeutics Inc. (OVID) |
|---|---|
| Event | Transition |
| Incoming | Charles Carter |
| Outgoing | Jeffrey Rona |
| Title in the filing | Chief Financial Officer, principal financial officer, principal accounting officer and secretary |
| Effective | July 6, 2026 |
| 8-K filed | July 8, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Senior Vice President of Finance and Financial Planning, Ovid Therapeutics Inc. |
| SEC CIK | 0001636651 |
Ovid Therapeutics Inc. reported this change in a Form 8-K, Item 5.02, filed July 8, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Charles Carter? Send a correction with the primary source.